Why the study?
Iron deficiency is associated with heart failure in a considerable proportion of patients, motivating an evaluation of ferric carboxymaltose to improve quality of life and reduce hospitalizations and mortality.
Does ferric carboxymaltose reduce hospitalizations or mortality in patients with heart failure and iron deficiency?
Does ferric carboxymaltose reduce hospitalizations or mortality in patients with heart failure and iron deficiency?
Answers are grounded in this paper and cite their sources.
Ferric carboxymaltose effectively reduces heart failure-related hospitalizations in patients with heart failure and iron deficiency, though it does not impact mortality.
Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure.
No takes yet. Share an insight, caveat, or question.
Rangwala et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: